Ocera Therapeutics, Inc. (OCRX) Receives Consensus Rating of “Hold” from Brokerages
Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) have been assigned an average rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $4.50.
OCRX has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Ocera Therapeutics in a report on Thursday, March 16th. Zacks Investment Research upgraded shares of Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Thursday, March 23rd. Finally, Aegis reiterated a “buy” rating and set a $3.00 target price on shares of Ocera Therapeutics in a report on Monday, April 17th.
TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/11/ocera-therapeutics-inc-ocrx-receives-consensus-rating-of-hold-from-brokerages.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. Hikari Power Ltd purchased a new position in shares of Ocera Therapeutics during the first quarter valued at $328,000. Renaissance Technologies LLC increased its position in shares of Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 33,300 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new position in shares of Ocera Therapeutics during the first quarter valued at $2,817,000. 20.91% of the stock is owned by institutional investors.
Shares of Ocera Therapeutics (NASDAQ:OCRX) traded down 0.8250% during midday trading on Tuesday, reaching $1.1901. The company had a trading volume of 34,668 shares. The company’s market capitalization is $31.55 million. The company has a 50 day moving average of $1.09 and a 200 day moving average of $1.32. Ocera Therapeutics has a one year low of $0.52 and a one year high of $3.15.
Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.04. Ocera Therapeutics had a negative net margin of 4,416.26% and a negative return on equity of 148.87%. Analysts predict that Ocera Therapeutics will post ($1.10) EPS for the current fiscal year.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.